These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 15561855

  • 21. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
    Barberán J, Mensa J.
    Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
    [Abstract] [Full Text] [Related]

  • 22. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [Abstract] [Full Text] [Related]

  • 23. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.
    Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A.
    J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500
    [Abstract] [Full Text] [Related]

  • 26. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D.
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [Abstract] [Full Text] [Related]

  • 27. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G, Gajjar D, Swan S, Marbury T, Grasela DM, Wang Z.
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [Abstract] [Full Text] [Related]

  • 28. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
    [Abstract] [Full Text] [Related]

  • 29. Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
    Salem AH, Noreddin AM.
    J Chemother; 2014 Apr; 26(2):80-5. PubMed ID: 24090676
    [Abstract] [Full Text] [Related]

  • 30. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S, Ianniello F, Leone S, Esposito S.
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [Abstract] [Full Text] [Related]

  • 31. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H, Chen M, Xu Y, Sun H, Yang Q, Hu Y, Cao B, Chu Y, Liu Y, Zhang R, Yu Y, Sun Z, Zhuo C, Ni Y, Hu B, Tan TY, Hsueh PR, Wang JH, Ko WC, Chen YH, Wahjono H.
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
    Low DE, Felmingham D, Brown SD, Rangaraju M, Nusrat R.
    J Infect; 2004 Aug; 49(2):115-25. PubMed ID: 15236918
    [Abstract] [Full Text] [Related]

  • 35. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E, Garau J.
    Respiration; 2005 Aug; 72(6):561-71. PubMed ID: 16354997
    [Abstract] [Full Text] [Related]

  • 36. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
    Fukuda Y, Takahata M, Sugiura Y, Shinmura Y, Nomura N.
    Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
    [Abstract] [Full Text] [Related]

  • 37. Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.
    Anguita-Alonso P, Rouse MS, Piper KE, Steckelberg JM, Patel R.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1263-7. PubMed ID: 16569838
    [Abstract] [Full Text] [Related]

  • 38. Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.
    Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J, Tanigawara Y.
    J Infect Chemother; 2013 Jun; 19(3):486-94. PubMed ID: 23525983
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat.
    Lees P.
    J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008
    [Abstract] [Full Text] [Related]

  • 40. Short-duration therapy for respiratory tract infections.
    Goff DA.
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.